Two randomised trials have shown potential benefits of blinatumomab in children and young adults with high-risk first relapse of B cell acute lymphoblastic leukaemia. The studies, both published in JAMA, also showed that use of the agent is likely to provide a less toxic option in those with chemotherapy-responsive disease. But only one of the ...
Two trials point to effectiveness and lower toxicity of blinatumomab in paediatric B-cell ALL
By Emma Wilkinson
5 Mar 2021